Neurosearch: We are keeping our options open
Increased demands from the FDA means that Neurosearch will need to be flexible in its negotiations with a possible partner. CEO admits that it will have consequences.
af KRESTEN MORTEN MUNKSGAARD
Anything could happen; that brief statement sums up the answers given by Patrick Dahlen, CEO of Neurosearch, after the company last week had to concede that it will be more difficult than initially thought to gain American approval for Huntexil, the company’s Huntington’s disease drug.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
